Alex Sapir - Dova Pharmaceuticals President CEO, Director
CEO
Mr. Alex Sapir is President, Chief Executive Officer, Director of the company since January 2017. From January 2006 to May 2016, Mr. Sapir served as Executive Vice President, Marketing and Sales for United Therapeutics Corporationrationration, a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and lifethreatening conditions. Prior to his time at United Therapeutics Corporationrationration, from January 2003 to January 2005 Mr. Sapir served as Senior Director, Marketing for Guilford Pharmaceuticals. He began his career at GlaxoSmithKline serving in various commercial roles in the United States and Europe. Mr. Sapir is a routine guest lecturer on the topic of pharmaceutical marketing strategy at Duke University Fuqua School of Business since 2017.
| Age | 50 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 919 748-5975 |
| Web | www.dova.com |
Dova Pharmaceuticals Management Efficiency
Dova Pharmaceuticals' management efficiency ratios could be used to measure how well Dova Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.25 M in liabilities with Debt to Equity (D/E) ratio of 43.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dova Pharmaceuticals has a current ratio of 5.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dova Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Dova Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dova Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dova to invest in growth at high rates of return. When we think about Dova Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CEO Age | ||
| Leonard Schleifer | Regeneron Pharmaceuticals | 65 | |
| Sanjeev Luther | Eterna Therapeutics | 62 | |
| Fan Zhou | Visionary Education Technology | 58 | |
| Scott Shaw | Lincoln Educational Services | 61 | |
| Jeffrey Maggioncalda | Coursera | 55 | |
| Jason Spivey | Visionary Education Technology | 48 | |
| Stephen Wherry | Visionary Education Technology | 61 | |
| Matthew Kissner | John Wiley Sons | 70 | |
| Kimberly McWaters | Universal Technical Institute | 56 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -1.0E-4 |
Dova Pharmaceuticals Leadership Team
Elected by the shareholders, the Dova Pharmaceuticals' board of directors comprises two types of representatives: Dova Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dova. The board's role is to monitor Dova Pharmaceuticals' management team and ensure that shareholders' interests are well served. Dova Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dova Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Goldman, Independent Director | ||
| Douglas Blankenship, CFO | ||
| Alfred Novak, Independent Director | ||
| Alex Sapir, President CEO, Director | ||
| Lee Allen, Chief Medical Officer | ||
| Sean Stalfort, Director | ||
| Kevin Laliberte, Senior Vice President - Product Development | ||
| Roger Jeffs, Independent Director | ||
| David Zaccardelli, President CEO | ||
| Nancy Wysenski, Independent Director | ||
| Mark Hahn, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Paul Manning, Chairman of the Board | ||
| Jason Hoitt, Chief Commercial Officer |
Dova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dova Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | (541.38) % | |||
| Current Valuation | 380.37 M | |||
| Shares Outstanding | 28.8 M | |||
| Shares Owned By Insiders | 62.25 % | |||
| Shares Owned By Institutions | 40.63 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Earning | (12.63) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dova Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dova Pharmaceuticals' short interest history, or implied volatility extrapolated from Dova Pharmaceuticals options trading.
Pair Trading with Dova Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dova Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dova Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Dova Stock
If you are still planning to invest in Dova Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dova Pharmaceuticals' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |